



**ECDC TECHNICAL REPORT**

## **A systematic literature review of interventions to increase linkage to care and adherence to treatment for hepatitis B and C, HIV and tuberculosis among people who inject drugs**

Supplement: List of included full text studies, list of excluded full text studies with reason and list of ongoing, withdrawn, and completed studies

From the package of technical documents published in conjunction with the joint ECDC and EMCDDA update of the guidance, 'Prevention and control of infectious diseases among people who inject drugs' (2023)

# Contents

Contents.....	2
List of included full text studies.....	3
Hepatitis C (HCV).....	3
Human Immunodeficiency Virus (HIV).....	4
Tuberculosis (TB).....	4
List of excluded full text studies with main reason.....	5
Wrong population.....	5
≤ 50 % PWID/OST.....	6
Wrong/no intervention.....	7
Wrong/no control.....	8
Ineligible outcome data.....	9
Wrong study design.....	10
Wrong study duration.....	11
Wrong country.....	11
No full text/posters.....	11
Repeated/duplicates.....	15
List of ongoing, withdrawn, and completed studies.....	17
HCV/HVB - ongoing, withdrawn, and completed studies.....	17
HIV/HCV - ongoing, withdrawn, and completed studies.....	23
TB – ongoing, withdrawn, and completed TB studies.....	30

## List of included full text studies

### Hepatitis C (HCV)

- Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: a Randomized Controlled Trial. *Ann Intern Med*. 2019;170(9):594-603.
- Arain A, De Sousa J, Corten K, Verrando R, Thijs H, Mathei C, et al. Pilot Study: combining Formal and Peer Education with FibroScan to Increase HCV Screening and Treatment in Persons who use Drugs. *J Subst Abuse Treat*. 2016;67:44-9.
- Broad J, Mason K, Guyton M, Lettner B, Matelski J, Powis J. Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada. *Int J Drug Policy*. 2020;80:102755.
- Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. *Am J Drug Alcohol Abuse*. 2012;38(3):206-12.
- Christensen S, Buggisch P, Mauss S, Boker KHW, Schott E, Klinker H, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? *Addiction*. 2018;113(5):868-82.
- Coffin PO, Santos GM, Behar E, Hern J, Walker J, Matheson T, et al. Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs. *PLoS One*. 2019;14(6):e0217471.
- Cooper CL, Hatashita H, Corsi DJ, Parmar P, Corrin R, Garber G. Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients. *Ann Hepatol*. 2017;16(6):874-80.
- Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, et al. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: analysis of Phase 3 ION Trials. *Clin Infect Dis*. 2016;63(11):1405-11.
- Ho SB, Brau N, Cheung R, Liu L, Sanchez C, Sklar M, et al. Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse. *Clin Gastroenterol Hepatol*. 2015;13(11):2005-14.e1-3.
- Lewis H, Kunkel J, Axten D, Dalton J, Gardner H, Tippett A, et al. Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment. *Eur J Gastroenterol Hepatol*. 2016;28(11):1258-63.
- Marinho RT, Costa A, Pires T, Raposo H, Vasconcelos C, Polonia C, et al. A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. *BMC Infect Dis*. 2016;16(1):565.
- Messina V, Russo A, Parente E, Russo G, Raimondo T, Salzillo A, et al. Innovative procedures for micro-elimination of HCV infection in persons who use drugs. *J Viral Hepat*. 2020;27(12):1437-43.
- Norton BL, Bachhuber MA, Singh R, Agyemang L, Arnsten JH, Cunningham CO, Litwin AH. Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: a pilot study. *Int J Drug Policy*. 2019;69:1-7.
- Radley A, de Bruin M, Inglis S, Donnan P, Hapca A, Barclay S, et al. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. *Lancet Gastroenterol Hepatol*. 2020;5(9):809-18.
- Reimer J, Schmidt CS, Schulte B, Gansefort D, Gözl J, Gerken G, et al. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial. *Clin Infect Dis*. 2013;57 Suppl 2(Suppl 2):S97-104.

Saiz de la Hoya P, Portilla J, Marco A, Garcia-Guerrero J, Faraco I, Anton J, et al. Directly observed therapy for chronic hepatitis C: a randomized clinical trial in the prison setting. *Gastroenterol Hepatol*. 2014;37(8):443-51.

Schmidbauer C, Schubert R, Schutz A, Schwanke C, Luhn J, Gutic E, et al. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. *PLoS One*. 2020;15(3):e0229239.

Starbird LE, Budhathoki C, Han HR, Sulkowski MS, Reynolds NR, Farley JE. Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial. *J Viral Hepat*. 2020;27(4):376-86.

Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, et al. Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs. *Clin Infect Dis*. 2020[e-pub 2019];70(9):1900-6.

Ward KM, Falade-Nwulia O, Moon J, Sutcliffe CG, Brinkley S, Haselhuhn T, et al. A randomized controlled trial of cash incentives or peer support to increase HCV treatment for persons with HIV who use drugs: The CHAMPS study. *Open Forum Infect Dis*. 2019;6(4):ofz166.

## Human Immunodeficiency Virus (HIV)

Babudieri S, Dorrucchi M, Boschini A, Carbonara S, Longo B, Monarca R, et al. Targeting candidates for directly administered highly active antiretroviral therapy: benefits observed in HIV-infected injecting drug users in residential drug-rehabilitation facilities. *AIDS Patient Care and STDs*. 2011;25(6): 359-364.

Masyukova MI, Hanna DB, Fox AD. HIV treatment outcomes among formerly incarcerated transitions clinic patients in a high prevalence setting. *Health Justice*. 2018;6(1): 16.

Sanchez GV, Llibre JM, Torrens M, Sanvisens A, Mateu G, Knobel H, et al. Effectiveness of antiretroviral therapy in HIV-1-infected active drug users attended in a drug abuse outpatient treatment facility providing a multidisciplinary care strategy. *Current HIV Research*. 2012;10(4): 356-363.

Tu D, Belda P, Littlejohn D, Pedersen JS, Valle-Rivera J, Tyndall M. Adoption of the chronic care model to improve HIV care: in a marginalized, largely aboriginal population. *Canadian Family Physician*. 2013;59(6): 650-657.

## Tuberculosis (TB)

Duarte R, Santos A, Mota M, Carvalho A, Marques A, Barros H. Involving community partners in the management of tuberculosis among drug users. *Public Health*. 2011;125(1): 60-62.

# List of excluded full text studies with main reason

## Wrong population

Criteria	Inclusion	Exclusion
Study population	<ul style="list-style-type: none"> <li>At least 50% of study sample were comprised of PWID or people on OST (age 14 and older, any sex)</li> <li>PWID with co-infections HCV, HBV, HIV, TB</li> </ul>	Wrong study population

Browne SH, Umlauf A, Tucker AJ, Low J, Moser K, Gonzalez Garcia J, et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. *PLoS Medicine*. 2019;16(10): e1002891.

Colasanti J, Sumitani J, Christina Mehta C, Zhang Y, Nguyen ML, Del Rio C, et al. Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States. *Open Forum Infect Dis*. 2018;5(6): ofy104.

DuChane J, Clark B, Hou J, Fitzner K, Pietrandoni G, Duncan I. Impact of HIV-specialized pharmacies on adherence to medications for comorbid conditions. *Journal of the American Pharmacists Association: JAPhA*. 2014;54(5): 493-501.

Finocchiaro-Kessler S, Catley D, Thomson D, Bradley-Ewing A, Berkley-Patton J, Goggin K. Patient communication tools to enhance ART adherence counseling in low and high resource settings. *Patient Education & Counseling*. 2012;89(1): 163-70.

Hosek SG, Harper GW, Lemos D, Burke-Miller J, Lee S, Friedman L, et al. Project ACCEPT: Evaluation of a Group-Based Intervention to Improve Engagement in Care for Youth Newly Diagnosed with HIV. *AIDS & Behavior*. 2018;22(8): 2650-61.

Kalichman SC, Cherry C, Kalichman MO, Eaton LA, Kohler JJ, Montero C, et al. Mobile Health Intervention to Reduce HIV Transmission: A Randomized Trial of Behaviorally Enhanced HIV Treatment as Prevention (B-TasP). *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 2018;78(1): 34-42.

Leo S, Brown-Gentry K, Makanji H, et al. Impact of a smartphone-based artificial intelligence platform on hepatitis C adherence in a real-world population (Abstract). *Proceedings of AMCP Managed Care & Specialty Pharmacy Annual Meeting*; 2019 Mar 25-28; San Diego, United States. Available at: <https://www.jmcp.org/doi/pdf/10.18553/jmcp.2019.25.3-a.s1>

Melvin SC, Gipson J. The Open Arms Healthcare Center's Integrated HIV Care Services Model. *Preventing Chronic Disease*. 2019;16: E135.

Moore DJ, Pasipanodya EC, Umlauf A, Rooney AS, Gouaux B, Depp CA, et al. Individualized texting for adherence building (ITAB) for methamphetamine users living with HIV: A pilot randomized clinical trial. *Drug and Alcohol Dependence*. 2018;189: 154-60.

Murphy P, Cocohoba J, Tang A, Pietrandoni G, Hou J, Guglielmo BJ. Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. *AIDS Patient Care & Stds*. 2012;26(9): 526-31.

Myers JJ, Dufour M-SK, Koester KA, Morewitz M, Packard R, Klein KM, et al. The effect of patient navigation on the likelihood of engagement in clinical care for HIV-infected individuals leaving jail. *American Journal of Public Health*. 2018;108(3): 385-92.

Perera AI, Thomas MG, Moore JO, Faasse K, Petrie KJ. Effect of a smartphone application incorporating personalized health-related imagery on adherence to antiretroviral therapy: a randomized clinical trial. *AIDS Patient Care & Stds*. 2014;28(11): 579-86.

Rajabiun S, Tryon J, Feaster M, Pan A, McKeithan L, Fortu K, et al. The influence of housing status on the HIV continuum of care: Results from a multisite study of patient navigation models to build a medical home for people living with HIV experiencing homelessness. *American Journal of Public Health*. 2018;108(S7): S539-S545.

Rowell-Cunsolo TL, Hong HK, Mkuu R, Britton A. Improving Medication Adherence Among Drug-Using HIV-Infected Formerly Incarcerated Individuals: A Pilot Test of Two Interventions. *Journal of correctional health care*. 2020;26(1): 42-54.

Safren SA, Bedoya CA, O'Cleirigh C, Biello KB, Pinkston MM, Stein MD, et al. Cognitive behavioural therapy for adherence and depression in patients with HIV: a three-arm randomised controlled trial. *Lancet HIV*. 2016;3(11):e529-e538.

Scott Sutton S, Magagnoli J, Hardin JW. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy. *Pharmacotherapy: The Journal of Human Pharmacology & Drug Therapy*. 2016;36(4): 385-401.

Swendeman D, Ramanathan N, Baetscher L, Medich M, Scheffler A, Comulada W, et al. Smartphone self-monitoring to support self-management among people living with HIV: Perceived benefits and theory of change from a mixed-methods randomized pilot study. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2015;69(Suppl 1): S80-S91.

Visaria J, Frazee SG. Role of pharmacy channel in adherence to hepatitis C regimens. *American Journal of Pharmacy Benefits*. 2013;5(1): 17-25.

## ≤ 50 % PWID/OST

Criteria	Inclusion	Exclusion
Study population	<ul style="list-style-type: none"> <li>At least 50% of study sample were comprised of PWID or people on OST (age 14 and older, any sex)</li> <li>PWID with co-infections HCV, HBV, HIV, TB</li> </ul>	Wrong study population

Cid-Silva P, Margusino-Framinan L, Balboa-Barreiro V, Pernas-Souto B, Mena-De-Cea A, Martin-Herranz I, et al. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines. *Journal of the International Association of Providers of AIDS Care*. 2019;18: 2325958218821940

Gardner LI, Giordano TP, Marks G, Wilson TE, Craw JA, Drainoni ML, et al. Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. *Clinical Infectious Diseases*. 2014;59(5): 725-34.

Groessl EJ, Liu L, Sklar M, Ho SB. HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals. *International Journal of Hepatology*. 2017;2017: 5834182.

Hanna DB, Hessol NA, Golub ET, Cocohoba JM, Cohen MH, Levine AM, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 2014;65(5): 587-96.

Hemmy Asamsama O, Squires L, Tessema A, Rae E, Hall K, Williams R, et al. HIV Nurse Navigation: Charting the Course to Improve Engagement in Care and HIV Virologic Suppression. *Journal of the International Association of Providers of AIDS Care*. 2017;16(6): 603-7.

Himelhoch S, Kreyenbuhl J, Palmer-Bacon J, Chu M, Brown C, Potts W. Pilot feasibility study of Heart2HAART: a smartphone application to assist with adherence among substance users living with HIV. *AIDS care*. 2017;29(7): 898-904.

Horvath KJ, Oakes J, Simon Rosser B, Danilenko G, Vezina H, Amico K, et al. Feasibility, acceptability and preliminary efficacy of an online peer-to-peer social support ART adherence intervention. *AIDS and behavior*. 2013;17(6): 2031-44.

Ingersoll KS, Dillingham RA, Hetteema JE, Conaway M, Freeman J, Reynolds G, et al. Pilot RCT of bidirectional text messaging for ART adherence among nonurban substance users with HIV. *Health psychology*. 2015;34S: 1305-15.

Khawcharoenporn T, Cole J, Claus J, Bell T, Lewis A, Zawitz C, et al. A randomized controlled study of intervention to improve continuity care engagement among HIV-infected persons after release from jails. *AIDS Care*. 2019;31(7):777-784.

Kral AH, Lambdin BH, Comfort M, Powers C, Cheng H, Lopez AM, et al. A Strengths-Based Case Management Intervention to Reduce HIV Viral Load Among People Who Use Drugs. *AIDS & Behavior*. 2018;22(1): 146-53.

Marks G, O'Daniels C, Grossman C, Crepaz N, Rose CE, Patel U, et al. Evaluation of a computer-based and counseling support intervention to improve HIV patients' viral loads. *AIDS care*. 2018;30(12): 1605-13.

Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, et al. Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial. *JAMA*. 2016;316(2): 156-70.

Mitrani VB, Feaster DJ, Weiss-Laxer NS, McCabe BE. Malaise, motivation and motherhood: predictors of engagement in behavioral interventions from a randomized controlled trial for HIV+ women in drug abuse recovery. *AIDS and behavior*. 2011;15(2): 396-406.

Pollock S, Toegel F, Holtyn AF, Rodewald AM, Leoutsakos JM, Fingerhood M, et al. Effects of incentives on viral suppression in people living with HIV who use cocaine or opiates. *Drug & Alcohol Dependence*. 2020;212: 108000.

Ricks PM, Hershov RC, Rahimian A, Huo D, Johnson W, Prachand N, et al. A randomized trial comparing standard outcomes in two treatment models for substance users with tuberculosis. *International journal of tuberculosis and lung disease*. 2015;19(3): 326-32.

Saeed S, Strumpf E, Moodie E, Cox J, Walmsley S, Cooper C, et al. Eliminating a structural barrier: Impact of removing fibrosis stage restrictions on hepatitis C treatment uptake among people co-infected with HIV. *Canadian Liver Journal*. 2019;2(2): 62-3.

Sayegh CS, MacDonell KK, Clark LF, Dowshen NL, Naar S, Olson-Kennedy J, et al. The Impact of Cell Phone Support on Psychosocial Outcomes for Youth Living with HIV Nonadherent to Antiretroviral Therapy. *AIDS & Behavior*. 2018;22(10): 3357-62.

Stagg HR, Surey J, Francis M, MacLellan J, Foster GR, Charlett A, et al. Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention. *BMC Medicine*. 2019;17(1): 71.

Tarantino N, Whiteley L, Craker L, Arnold TL, Mena LA, Brown LK. Measuring antiretroviral adherence among young people living with HIV: Observations from a real-time monitoring device versus self report. *Journal of Adolescent Health*. 2018;62(2): S7.

Uuskula A, Laisaar K-T, Raag M, Lemsalu L, Lohmus L, Ruutel K, et al. Effects of counselling on adherence to antiretroviral treatment among people with HIV in Estonia: A randomized controlled trial. *AIDS and behavior*. 2018;22(1): 224-33.

## Wrong/no intervention

Criteria	Inclusion	Exclusion
Intervention	<ul style="list-style-type: none"> <li>Any intervention aimed at enhancing linkage to care targeting PWID/people on OST in any setting</li> <li>Any intervention aimed at enhancing adherence to treatment targeting PWID/people on OST in any setting</li> </ul>	<ul style="list-style-type: none"> <li>Public health interventions targeting health care providers as opposed to individuals</li> <li>Interventions targeting testing</li> </ul>

Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, et al. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. *Substance Abuse Treatment, Prevention, & Policy*. 2020;15(1): 44.

Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Ellen Harrod M, et al. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveLife study. *Journal of Viral Hepatitis*. 2020;27(3): 281-93.

Blashill AJ, Gordon JR, Safren SA. Depression longitudinally mediates the association of appearance concerns to ART non-adherence in HIV-infected individuals with a history of injection drug use. *Journal of Behavioral Medicine*. 2014;37(1): 166-72.



- Brust JC, Litwin AH, Berg KM, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance. *AIDS Research and Human Retroviruses*. 2011;27(5): 535-41.
- Chartier M, Maier M. Engagement Along the HIV Care Continuum and the Potential Role of Mental Health and Substance Use Disorders. *Federal Practitioner*. 2015;32(Suppl 2): 10S-4S.
- Chromy D, Mandorfer M, Bauer D, Schwabl P, Simbrunner B, Schmidbauer C, et al. Success of unrestricted DAA therapy is limited by HCV reinfections and loss to follow-up in HIV-positive patients. *HIV Medicine*. 2019;20: 292.
- Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, et al. Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. *Clinical Infectious Diseases*. 2020;71(7):e115-e124.
- Harris AM, Millman AJ, Lora M, Osinubi A, Lom J, Miller LS. Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients. *Vaccine*. 2019;37(16): 2188-93.
- Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, et al. Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study. *Clinical Infectious Diseases*. 2020;71(6):1502-1510.
- Perlman DC, Jordan AE, McKnight C, Young C, Delucchi KL, Sorensen JL, et al. Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions. *Journal of addictive diseases*. 2014;33(4): 322-31.
- Ruutel K, Loit HM, Sepp T, Kliiman K, McNutt LA, Uuskula A. Enhanced tuberculosis case detection among substitution treatment patients: a randomized controlled trial. *BMC research notes*. 2011;4(1): 192.
- Traeger MW, Pedrana AE, van Santen DK, Doyle JS, Howell J, Thompson AJ, et al. The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services. *PLoS ONE*. 2020;15(6): e0235445.
- Tsui JI, Walley AY, Cheng DM, Lira MC, Liebschutz JM, Forman LS, et al. Provider opioid prescribing practices and the belief that opioids keep people living with HIV engaged in care: a cross-sectional study. *AIDS care*. 2019;31(9): 1140-4.
- Weiser J, Beer L, Frazier EL, Patel R, Dempsey A, Hauck H, et al. Service Delivery and Patient Outcomes in Ryan White HIV/AIDS Program-Funded and -Nonfunded Health Care Facilities in the United States. *JAMA Internal Medicine*. 2015;175(10): 1650-9.

## Wrong/no control

Criteria	Inclusion	Exclusion
Comparator	<ul style="list-style-type: none"> <li>PWID or OST comparator group with no intervention or receiving usual or routine care as defined by study authors</li> </ul>	Non-PWID or non-OST or comparator group receiving intervention/not receiving usual or routine care

- Agarwal A, Dang S, Aduli F, Golden W. Impact of case management of chronic hepatitis C (HCV) treatment in a state medicaid program. *American Journal of Gastroenterology*. 2011;106: S429.
- Akiyama MJ, Columbus D, Macdonald R, Jordan AO, Schwartz J, Litwin AH, et al. Implementation and evaluation of a care coordination program for patients with hepatitis C following release from New York City jails. *ClinicalTrials.gov*. 2019;66: 540A. Available from: <https://clinicaltrials.gov/ct2/show/study/NCT04036760>
- Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. *Drug and Alcohol Dependence*. 2011;113(2-3):192-199.
- Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. *Journal of substance abuse treatment*. 2017;75: 49-53.
- Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, et al. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. *BMC Infectious Diseases*. 2017;17(1): 420.



Falade-Nwulia O, Ward KM, McCormick S, Mehta SH, Pitts SR, Katz S, et al. Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. *Journal of Viral Hepatitis*. 2020;27(7): 663-70.

Jessop AB, Bass SB, Brajuha J, Alhajji M, Burke M, Gashat MT, et al. "Take Charge, Get Cured": pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy. *Journal of substance abuse treatment*. 2020;109: 23-33.

Lambers FA, Stolte IG, van den Berg CH, Coutinho RA, Prins M. Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam. *International Journal of Drug Policy*. 2011;22(3): 210-8.

O'Sullivan M, Jones AM, Gage H, Jordan J, MacPepple E, Williams H, et al. ITTREAT (Integrated Community Test - Stage - TREAT) Hepatitis C service for people who use drugs: Real-world outcomes. *Liver International*. 2020;40(5): 1021-31.

Seidenberg A, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. *BMC Infectious Diseases*. 2013;13: 9.

Stitzer M, Matheson T, Cunningham C, Sorensen JL, Feaster DJ, Gooden L, et al. Enhancing patient navigation to improve intervention session attendance and viral load suppression of persons with HIV and substance use: a secondary post hoc analysis of the Project HOPE study. *Addiction science & clinical practice*. 2017;12(1): 16.

Stitzer ML, Gukasyan N, Matheson T, Sorensen JL, Feaster DJ, Duan R, et al. Enhancing patient navigation with contingent financial incentives for substance use abatement in persons with HIV and substance use. *Psychology of Addictive Behaviors*. 2020;34(1): 23-30.

Stitzer ML, Hammond AS, Matheson T, Sorensen JL, Feaster DJ, Duan R, et al. Enhancing Patient Navigation with Contingent Incentives to Improve Healthcare Behaviors and Viral Load Suppression of Persons with HIV and Substance Use. *AIDS Patient Care and STDs*. 2018;32(7): 288-96.

Wohl DA, Allmon AG, Evon D, Hurt C, Reifeis SA, Thirumurthy H, et al. Financial incentives for adherence to hepatitis C virus clinical care and treatment: A randomized trial of two strategies. *Open Forum Infectious Diseases*. 2017;4(2): ofx095.

## Ineligible outcome data

Criteria	Inclusion	Exclusion
Study outcomes	<ul style="list-style-type: none"> <li>Data on at least one of the outcomes listed in the specific PICO schemes must be reported</li> </ul>	None of the defined study outcomes included/ineligible outcomes, no data available

Bamford L, Benitez J, Munoz-Laboy M. Providing HIV Comprehensive Care to Latino/as Who Inject Drugs: Philadelphia, 2013-2018. *American Journal of Public Health*. 2019;109(02. Jan): 273-5.

Ghose T, Shubert V, Poitevien V, Choudhuri S, Gross R. Effectiveness of a Viral Load Suppression Intervention for Highly Vulnerable People Living with HIV. *AIDS & Behavior*. 2019;23(9): 2443-52.

Harrison GI, Murray K, Gore R, Lee P, Sreedharan A, Richardson P, et al. The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. *Addiction*. 2019;114(6): 1113-22.

Laisaar K-T, Uuskula A, Sharma A, DeHovitz JA, Amico K. Developing an adherence support intervention for patients on antiretroviral therapy in the context of the recent IDU-driven HIV/AIDS epidemic in Estonia. *AIDS care*. Jul.05;25(7): 863-73.

Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. *Liver International*. 2013;33(7): 999-1007.

Maticic M, Selic Kurincic T, Kastelic A, Poljak M, Lesnicar G, Meglic-Volkar J, et al. A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia: High enrollement, adherence and sustained virological response. *Suchtmedizin in Forschung und Praxis*. 2013;15(4): 245.

Mohd Salleh NA, Fairbairn N, Nolan S, Barrios R, Shoveller J, Richardson L, et al. Dispensation of antiretroviral therapy and methadone maintenance therapy at the same facility in a low-barrier setting linked to optimal adherence to HIV treatment. *HIV Medicine*. 2019;20(9): 606-14.

Nahvi S, Litwin AH, Heo M, Berg KM, Li X, Arnsten JH. Directly observed antiretroviral therapy eliminates adverse effects of active drug use on adherence. *Drug & Alcohol Dependence*. 2012;120(1-3): 174-80.

Sacks S, McKendrick K, Vazan P, Sacks JY, Cleland CM. Modified therapeutic community aftercare for clients triply diagnosed with HIV/AIDS and co-occurring mental and substance use disorders. *AIDS care*. 2011;23(12): 1676-86.

Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. *Journal of consulting and clinical psychology*. 2012;80(3): 404-15.

## Wrong study design

Criteria	Inclusion	Exclusion
Study design/type	Randomised controlled trials (RCTs), Non-randomized control trials, prospective and retrospective cohort studies and case-control studies incl. convenience sampling <sup>1</sup>	Wrong study design: Non-comparative studies with no control, Case studies, case reports, Animal studies, Ineligible methodologies, Epidemiology studies, Review studies used for citation check

Hirsch-Moverman Y. TB or not TB: Treatment of latent tuberculosis infection in Harlem, New York. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2011;72(6-B): 3321.

Messina V, Russo A, Simeone F, Salzillo A, Pisaturo M, Di Caprio G, et al. High rate of sustained virological response in persons who inject drug (PWID) using an innovative procedure: A case-control study. *Hepatology*. 2019;70(S1): 962A.

Mukandavire C, Low A, Mburu G, Trickey A, May MT, Davies CF, et al. Impact of opioid substitution therapy on the HIV prevention benefit of antiretroviral therapy for people who inject drugs. *AIDS*. 2017;31(8): 1181-90.

Pearson FS, Shafer MS, Dembo R, Del Mar Vega-Debien G, Pankow J, Duvall JL, et al. Efficacy of a process improvement intervention on delivery of HIV services to offenders: a multisite trial. *American Journal of Public Health*. 2014;104(12): 2385-91.

Stitzer M, Calsyn D, Matheson T, Sorensen J, Gooden L, Metsch L. Development of a Multi-Target Contingency Management Intervention for HIV Positive Substance Users. *Journal of substance abuse treatment*. 2017;72: 66-71.

Walker JG, Kuchuloria T, Sergeenko D, Fraser H, Lim AG, Shadaker S, et al. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. *The Lancet Global Health*. 2020;8(2): e244-e53.

Ward Z, Reynolds R, Campbell L, Martin NK, Harrison G, Irving W, et al. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England. *Addiction*. 2020;115(8): 1509-21.

## Wrong study duration

Criteria	Inclusion	Exclusion
Study duration	<b>Adherence:</b> HCV: at least 3 months; HBV/TB/HIV: at least one year/or follow up 1 year	<b>Adherence:</b> HCV: Less than 3 months; HBV/TB/HIV: less than one year/or follow up 1 year

Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. *Drug and Alcohol Dependence*. 2011;113(2-3): 192-9.

Dale SK, Traeger L, O'Cleirigh C, Bedoya C, Pinkston M, Wilner JG, et al. Baseline substance use interferes with maintenance of HIV medication adherence skills. *AIDS Patient Care and STDs*. 2016;30(5): 215-20.

Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J, Heckman CJ, Ceperich SD, Hettema J, et al. A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users. *Drug and Alcohol Dependence*. 2011;116(1-3): 177-87.

Wimberly AS, Gross R, Layde M. Effect of Yoga on Antiretroviral Adherence Postincarceration in HIV+ Individuals. *Journal of correctional health care*. 2020;26(1): 83-94.

## Wrong country

Criteria	Inclusion	Exclusion
Country of study	EU/EEA/EFTA countries + candidate countries + UK + US + CA + AU + NZ	All other countries

Morozova O, Dvoryak S, Altice FL. Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine. *International Journal of Drug Policy*. 2013;24(6): e91-e8.

K, Ishibashi M, Matsumoto T, Ohishi K, Muraki Y, Iwamoto T, et al. Impact of physician-pharmacist collaborative protocol-based pharmacotherapy management for HIV outpatients: A retrospective cohort study. *Journal of Pharmaceutical Health Care and Sciences*. 2020;6:9.

## No full text/posters

Criteria	Inclusion	Exclusion
Publication type	Full study publication available	Conference abstracts, study protocols, studies not peer-reviewed, repeated/duplicate results

Jacobs P, Feaster D, Pan Y, Gooden L, del Rio C, Daar E. Starting ART in HIV+ drug users while hospitalized predicts HIV treatment engagement. Conference: 25th Conference on Retroviruses and Opportunistic Infections, CROI 2018. United States. *Topics in Antiviral Medicine*. 2018; 26(S1): 511s-2s.

Alam I, Alam ZT; Improving PWID Hepatitis C care cascade through electronic health engagement. *Journal of Addiction Medicine*. 2019;13(3): E30.

Asher AK, Evans J, Hahn JA, Briceno A, Page K. Behavioral risk changes in young people who inject drugs following rapid HCV testing. *Hepatology*. 2014;60: 1061A.

Attonito J. The influence of neurocognitive impairment, alcohol and other drug (AOD) use, and psychosocial factors on antiretroviral treatment adherence, service utilization and viral load among HIV-seropositive adults. *Dissertation Abstracts International: Section B: The Sciences and Engineering*. 2014;75(5-B(E)).

Baltzer Turje R, Barrios R, Payne M, Simpson D, Jamal R, Clarke C, et al. Results from a quality improvement initiative to improve antiretroviral therapy adherence at North American's only HIV/AIDS health care facility that incorporates supervised injection services into an integrated HIV/AIDS health care program. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2012;23: 75A.

Bielen R, Verrando R, Penders J, Oris E, Nevens F, Robaey G. Case management to improve uptake for screening and therapy of Hepatitis C viral infection in people who inject drugs. *Hepatology*. 2016;64(1): 411A-2A.

- Busari O, Adeyemi A, Nakayima M. Novel modular teaching of HIV patients in resource-limiting setting: Effect of learning outcomes on adherence to highly active antiretroviral therapy (HAART). *Sexually Transmitted Infections*. 2011;87: A332.
- Cantudo-Cuenca M, Haro Marquez C, Cantudo-Cuenca M, Gonzalez-Medina M, Gomez-Pera C, Trisancho-Perez AM, et al. Adherence to long-term medicines in HIV-Infected patients. *European Journal of Hospital Pharmacy*. 2015;22(S1): A4-A5.
- Chan PPY, Mohsen W, Whelan M, Glass A, Ladera A, Mouton M, et al. Project ECHO: A novel tele-mentoring service to aid hepatitis C treatment in difficult-to-access populations. *Journal of Gastroenterology and Hepatology (Australia)*. 2017;32: 67.
- Charlot H, Trabut JB, Barrault C, Kini-Matondo W, Causse R, Francois M, et al. Green light for compliance in patients treated for hepatitis C and addiction. *International Journal of Clinical Pharmacy*. 2016;38(5): 1337.
- Chehl NJ, Maheshwari A, Yoo HY, Cook C, Savva Y, Brown S, et al. Compliance and treatment success rates with DAA for HCV patients are higher in structured HCV clinic when compared to general hepatology clinics. *Hepatology*. 2018;68: 296A-7A.
- Cockern S, Naar S, Woods S, Outlaw A, Ellis D, MacDonell K, et al. Translating the neuroscience of prospective memory into a new adherence intervention for youth with HIV. *Psychosomatic Medicine*. 2015;77(3): A127.
- Corless L, Gao-Du Y. Managing hepatitis C virus infection in prison-same disease, different barriers. *Gut*. 2017;66: A103.
- Doyle J, Dietze P, Stooze M, Higgs P, Desmond P, Iser D, et al. Community-based hepatitis C treatment of people who inject drugs and their injecting network is feasible and effective: Results from the TAP (Treatment and Prevention) study. *Journal of Hepatology*. 2019;70(1): e495.
- Drozd W, Dybowska D, Kozielowicz D, Halota W, Borkowska A. Psychopharmacological treatment may affect the efficacy of antiviral treatment in patients with chronic hepatitis C. *European Neuropsychopharmacology*. 2011;21: S138-S9.
- Fox AD, Hawks LC, Norton BL, Litwin AH, Cunningham C. Integrated care increases evaluation but not treatment for chronic hepatitis C virus infection in primary care. *Journal of General Internal Medicine*. 2015;30: S194-S5.
- Gao-Du Y, Brocklesby S, Corless L. Case finding can successfully re-engage persons lost to follow-up and increase treatment rates in hepatitis C virus services. *Journal of Hepatology*. 2018;68: S326.
- Glover C, Curtis S, Kirkwood S, McGinness P, Anderson P. Nurses at the forefront: A new HIV service model for people who inject drugs (PWIDs) in Glasgow. *Journal of the International AIDS Society*. 2018;21: 65.
- Goel A, Paulino L, Dieterich D, Perumalswami PV. High rates of hepatitis c virus infection among inpatient baby boomers in an urban hospital: A model to improve linkage to care. *Hepatology*. 2015;62: 481A.
- Gottfredsson M, Tyrfingsson T, Runarsdottir V, Bergmann OM, Bjornsson E, Johannsson B, et al. Increased intensity of testing and treatment for elimination of hepatitis C. real world experience from the treatment as prevention (TRAP HEPC) program in Iceland. *Hepatology*. 2017;66: 611A.
- Griffith DC, Dell S, Snyder J, Greenblatt S, Keruly JC, Agwu A. Youth-focused care in an adult clinic improves retention for young adults with HIV. *Topics in Antiviral Medicine*. 2018;26(S1): 504s.
- Gross P, Tu D, Tam T, Somlak Pedersen J, Bodenhamer S, Valle-Rivera J, et al. The impact of self-efficacy and treatment literacy on HIV treatment adherence in a marginalized inner-city population using a community-driven patient self-management support intervention. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2011;22: 66B.
- Hashim A, Bremner S, Macken L, Worthley T, Aithal GP, Verma S. A dedicated hostel-based community liver service for homeless and vulnerable adults: Valid (vulnerable adults liver disease) study. *Hepatology*. 2017;66: 318A.
- Hill K, Nussdorf L, Mathur P, Gross C, Silk R, Akoth E, et al. Impact of mat and housing status on patient-reported outcomes of HCV treatment in PWID. *Hepatology*. 2018;68: 350A.

- Ho SB, Groessl EJ, Brau N, Cheung R, Sanchez CM, Campbell N, et al. Integrated care for high risk psychiatric and substance use disorder patients with hepatitis C increases overall SVR rates: Final results of a prospective multisite randomized trial. *Hepatology*. 2013;58(4): 1295A.
- Ho SB, Groessl EJ, Brau N, Cheung R, Weingart KR, Ward M, et al. Multisite randomized trial of an Integrated Care (IC) model for HCV patients with psychiatric and substance use co-morbidities: Final results of impact on treatment initiation. *Hepatology*. 2012;56: 1000A-1A.
- Ho SB, Groessl EJ, Brau N, Cheung RC, Weingart KR, Ward MA, et al. Prospective multisite randomized trial of Integrated Care (IC) vs. Usual Care (UC) for improving access to antiviral therapy for high risk patients with chronic HCV. *Journal of Hepatology*. 2012;56: S386.
- Ho SB, Groessl EJ, Liu L, Sanchez CM, Wasil MM, Robinson SK. Randomized trial of integrated care to promote direct acting antiviral treatment among high risk hepatitis c patients with psychiatric and substance use disorders. *Journal of Hepatology*. 2014;60(1): S333.
- Hochstatter K, Landucci G, Gustafson D, Westergaard R. Using a mobile-health system to monitor and provide support along the hepatitis c virus continuum of care for people with opioid use disorders: Experience from a randomized trial. *Open Forum Infectious Diseases*. 2017;4: S201.
- Holeksa J, Bassi A, Alimohammadi A, Thiam A, Conway B. HCV treatment responses among people who use drugs: An evaluation of patients on and off opiate agonist therapy in a real-life setting. *Journal of Hepatology*. 2018;68: S274-S5.
- Horsley A, Vilar FJ, O'Shea G. Engaging the disengaged in a community clinic. *HIV Medicine*. 2016;17(S1): 31-2.
- Kunkel J, Lewis H, Wilkinson M, Foster GR. A novel nurse-led approach does not increase initiation of therapy in injection drug users with chronic hepatitis C in East London. *Hepatology*. 2013;58(S1): 340A-1A.
- Lepage CDJ, Garber G, Galanakis C, Corrin R, Cooper C. Telemedicine outcomes in the hepatitis C direct acting antiviral era. *Journal of Viral Hepatitis*. 2018;25: 56.
- Lewis H, Kunkel J, Wilkinson M, Foster GR. A novel nurse led model of treatment does not increase treatment rates in injection drug users with hepatitis C virus. *Journal of Hepatology*. 2014;60(S1): S522.
- Litwin AH, Agyemang L, Akiyama MJ, Norton BL, Heo M, Ning Y, et al. The PREVAIL Study: Intensive models of HCV care for people who inject drugs. *Journal of Hepatology*. 2017;66: S72.
- Litwin AH, Arnsten J, Heo M, Li X, Hidalgo J. Directly observed HCV treatment in methadone clinics-preliminary results. *Journal of the International Association of Physicians in AIDS Care*. 2011;10(3): 205.
- Litwin AH, Shafner L, Agyemang L. Smartphone based artificial intelligence platform demonstrates high rates of adherence and viral outcome in patients receiving fixed-dose ledipasvir and sofosbuvir: A pilot study. *Hepatology*. 2017;66: 862A.
- Llorca Fernandez R, Otero Fernández MA, Ampuero J, Rico MC, Fombuena B, Romero-Gomez M. Continuum of care of hepatitis C from detection to cure: Impact of peer-to-peer sessions in primary care. *Journal of Hepatology*. 2015;62: S616.
- Losikoff P, Gomes L, Coonan B, Rebello H, Mendenhall A, Hewitt T, et al. Treatment of hepatitis C infection in an office-based opiate treatment (OBOT) clinic. *Hepatology*. 2017;66: 624A.
- Magaldi L, Brown N, Coleman C, Dorshimer M, Kostman J, Zaret D, et al. Outcomes of hepatitis C testing, linkage to care, and treatment in a community based program in high versus low prevalence sites. *Journal of Hepatology*. 2018;68: S159.
- Maria Belen, F.I.M.B, Jose, Manuel F.O.J.M., Isabel M.C.I, Cristina G.P.C; Angeles, F.C.A; Elena S.Y.E; et al. The improvement of adherence to antiretroviral treatment through the pharmaceutical care and the analysis of factors affecting it. *European Journal of Hospital Pharmacy: Science and Practice*. 2012;19:242.
- Martel-Laferriere V, Brissette S, Juteau LC, Wartelle-Bladou C, Poppa M, Goyer ME, et al. Effect of a single-day investigation for HCV infection on treatment initiation among people who inject drugs (PWID). *Hepatology*. 2019;70(S1): 953A-4A.

- Mensa M, Amoroso P, Anglada H, Chaguaceda C, Sotoca JM, Martin M, et al. Improving chronic hepatitis B virus outcomes using a web and smartphone-based medication self-management platform. *European Journal of Hospital Pharmacy*. 2018;25: A85.
- Messina V, Russo A, Parente E, Russo G, Raimondo T, Di Caprio G, et al. The "CASERTA MODEL". An HCV way out in persons who use drugs (PWUD) in Italy. *Digestive and Liver Disease*. 2020;52: e28.
- Metcalf R, McAuley A, Wallace L, Hutchinson S, Goldberg D. Is early ART achievable in people who inject drugs (PWIDs) living with HIV? *Journal of the International AIDS Society*. 2018;21: 64.
- Metsch LR, Feaster DJ, Gooden L, Das M, Matheson T, Stitzer ML, et al. A patient navigation/contingency management RCT for hospitalized HIV+ substance users. *Topics in Antiviral Medicine*. 2016;24(E-1): 10.
- Arnsten J. Smartphone based aDOT treatment with fixed-dose elbasvir and grazoprevir in PWIDs. *ClinicalTrials.gov*. 2017. Available from: <https://clinicaltrials.gov/show/NCT03127358>.
- Olson MC, Pierce KA, Jacobson IM. A study to determine the efficacy of a telemedicine linkage visit as an extension of the medical home to increase rates of engagement in care for patients with substance use disorder and hepatitis C virus (HCV) infection. *Hepatology*. 2019;70 (S1): 137A.
- Ortiz M. Responding to the opioid epidemic: Improving the diagnosis of Hepatitis C virus infection with expanded screening. *Hepatology*. 2018;68: 894A-5A.
- Phillips C, Yusuf A. Increasing attendance and engagement of substance misuse clients with Hepatitis C. *Gut*. 2019;68: A225.
- Pogosky A, Wungjiranirun M, Molino J, Callahan M, Furtado C, Shittu Y, et al. Results of a Hepatitis C outreach initiative and identification of barriers to treatment. *American Journal of Gastroenterology*. 2019;114: S599.
- Pol S, Fouad F, Rodriguez I, Lemaitre M, Ansolabehere X, Lada O, et al. Patients treated for hepatitis C: An observational study with the French administrative health care database (SNDS). *Hepatology*. 2019;70(S1): 347A.
- Powell J, Masson C, Naugle J, Ricco M, Magee C, Zevin B, et al. Formal hepatitis C education enhances confidence in prevention of HCV transmission and interest in receipt of HCV treatment among people in homelessness shelters. *Hepatology*. 2019;70(S1): 456A-7A.
- Protopapas K, Kazakou P, Thomas K, Kavatha D, Chounta A, Zampetas G, et al. Improving the care cascade of hepatitis C management among HIV-HCV co-infected persons by facilitating access to direct acting agents (DAAs): A real-life, single centre experience. *Journal of the International AIDS Society*. 2018;21(S8): 166.
- Puttagunta R, Thoyakulathu E, Bogard S. Peer led discussions: A key element of care for young adults with HIV. *American Journal of Tropical Medicine and Hygiene*. 2015;93(4): 532.
- Rebhook G, Keatley J, Shade S, Maiorana A, Xavier J. Organizational and individual-level strategies associated with viral suppression in a sample of transgender women receiving care for HIV infection in the U.S. *Journal of the International AIDS Society*. 2019;22(S5): 17.
- Rosenthal E, Hill K, Nussdorf L, Mathur P, Gross C, Silk R, et al. Collocation of Buprenorphine with HCV treatment to improve adherence and reduce harm in PWID with HCV: Preliminary data from the ANCHOR study. *Journal of Hepatology*. 2018;68: S51.
- Rudel G, Finessi V, Nottaris A, Borojevic M, Messina P, Moriggia A. Comparison of different models of nursing care delivery in the management of hepatitis C treatment among people who inject drugs. *Journal of Hepatology*. 2018;68: S367.
- Gómez MR, Nieto CM, Herraiz ER, Gómez ED, Abanades MP, López-Matencio JS, et al. Impact on drug adherence and viral load after pharmaceutical intervention in selected hepatitis b outpatients. *European Journal of Hospital Pharmacy*. 2016;23(S1): A65.
- Saeed S, Moodie EE, Hull M, Walmsley S, Cooper C, Wong A, et al. Reductions in healthcare service usage following direct acting antiviral therapy. *Topics in Antiviral Medicine*. 2018;26: 262s.
- Schmidt CS, Schulte B, Gansefort D, Goelz J, Gerken G, Scherbaum N, et al. Optimizing HCV therapy: The impact of psychoeducation on retention and SVR in opiate substituted patients. *Hepatology*. 2011;54: 821A-2A.

- Stainbrook T, Naik S. Real-world experience treating hepatitis C virus (HCV) in patients on opioid substitution therapy in rural Pennsylvania. *Open Forum Infectious Diseases*. 2016;1: S69.
- Story A, Aldridge R, Smith C, Garber E, Hall J, Fernandez G, et al. A randomised controlled trial comparing smartphone enabled remote video observation with direct observation of treatment for tuberculosis. *Thorax*. 2017;72: A21.
- Stubbs H, O'Hara R, Glover C, Lavery L, Brown K, Metcalfe R, et al. Time to antiretroviral therapy: Service model adaptation during an outbreak of HIV in people who inject drugs (PWIDs). *HIV Medicine*. 2019;20: 52-3.
- Stuber M, Spence Gress C, Rodger D, Wong A. Clinic to community: Inter-professional collaboration in enhanced adherence to antiretroviral therapy. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2014;25: 54A-5A.
- Sulkowski M, Moon J, Sherman KE, Darling J, Muir A, Khalili M, et al. The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C- transforming decision-making for patients, providers, and stakeholders. *Journal of Hepatology*. 2019;70(1): e242.
- Teti E, Foroghi L, Malagnino V, Cento V, Stingone C, Compagno M, et al. Real world adherence to Direct-Acting Antivirals in a cohort of drug users in Rome, Italy. *Journal of Hepatology*. 2018;68: S285-S6.
- Tu D, Thumath MA, Demlow E, Chu T, Heath K, Yip B, et al. Impact of outreach testing and intensive case management on linkage and engagement in care as part of a comprehensive treatment as prevention (TasP) pilot in Vancouver, British Columbia. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2013;24: 93A.
- Tu D, Thumath MA, Demlow E, Chu T, Heath K, Yip B, et al. Intensive case management in Vancouver increases engagement to care and improves HIV outcomes for marginalized people living with HIV. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2013;24: 32A.
- Vasileiadi S, Papadopoulos N, Antonakaki P, Papavdi M, Spanoudaki A, Koustenis K, et al. Changes in characteristics of patients with chronic hepatitis C (CHC) and effectiveness of treatment uptake after universal access to direct-acting antivirals (DAAS). a greek paradigm on the path of elimination. *Hepatology*. 2019;70(S1): 399A.
- Veeramachaneni H, Park B, Miller L. Differences in inpatient and outpatient HCV prevalence and linkage to care rates in a safety net hospital Hepatitis C screening program. *Hepatology*. 2018;68: 914A-5A.
- Villanueva M, Rizk C, Shiferaw B, Ogbuagu O, Malinis M, Miceli J. Implementing a co-located HCV clinic within an HIV clinic: Four year experience. *Open Forum Infectious Diseases*. 2018;5: S660-S1.
- Wade A, Doyle J, Gane E, Stedman C, Draper B, Iser D, et al. Preliminary analysis of the Prime Study; A randomized controlled trial comparing the hepatitis C care cascade in primary care vs. tertiary care. *Journal of Hepatology*. 2018;68: S315.
- Wade A, Doyle J, Gane EJ, Stedman CA, Draper B, Iser DM, et al. Providing direct acting antiviral therapy in primary care increases treatment uptake: Results from the prime study, a randomized controlled trial, comparing the hepatitis C care cascade in primary care versus tertiary care. *Hepatology*. 2018;68: 302A-3A.
- Walker J, Gvinjilia L, Nasrullah M, Gamkrelidze A, Morgan J, Vickerman P. Interim evaluation and projected impact of the hepatitis C virus elimination program in Georgia. *Journal of Hepatology*. 2018;68: S142.
- Yaras S, Ucbilek E, Yilmaz I, Ozdogan O, Altintas E, Sezgin O. The real-life experience with directly acting antivirals in chronic hepatitis C treatment: A single center experience from Turkey. *Hepatology International*. 2018;12(2): S293.

## Repeated/duplicates

- Sulkowski M, Ward K, Falade-Nwulia O, Moon J, Sutcliffe C, Brinkley S, et al. Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfecting persons who inject drugs: The CHAMPS Study. *Journal of Hepatology*. 2017;66(1): S719.



Stagg HR, Surey J, Francis M, MacLellan J, Foster GR, Charlett A, et al. Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention. *BMC Medicine*. 2019;17(1): 71.

Ingersoll KS, Dillingham RA, Hettema JE, Conaway M, Freeman J, Reynolds G, et al. Pilot RCT of bidirectional text messaging for ART adherence among nonurban substance users with HIV. *Health psychology*. 2015;34: 1305-1315.

## List of ongoing, withdrawn, and completed studies

Information with status and main characteristics of the 57 ongoing, withdrawn, and completed studies identified in study registries, research programs or from handsearching are provided in the Tables below. For hepatitis C, 21 new or ongoing studies were identified, one focusing on both hepatitis C and B. In addition, 35 HIV studies in progress could have been found (mainly conducted in the United States and Canada). Furthermore, one ongoing tuberculosis study was identified.

### HCV/HVB – ongoing, withdrawn, and completed studies

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date*	Note/Associated publications
Accessible care intervention for engaging people who inject illicit drugs in hepatitis C virus care: Preliminary results from a randomised clinical trial	NA	US	RCT	65	Low-threshold care in a syringe service program versus usual care	unclear/preliminary results published, October 2019	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810993">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810993</a>
Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)	<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT03155906">study register, NCT03155906</a>	NO	RCT	240	Diagnostic and treatment follow-up for HCV treatment	ongoing/8 August 2022	<a href="https://pubmed.ncbi.nlm.nih.gov/31703669">https://pubmed.ncbi.nlm.nih.gov/31703669</a>
A Mobile Health Intervention to Improve Hepatitis C Outcomes Among People with Opioid Use Disorder	<a href="https://www.clinicaltrials.gov/ct2/show/study/NCT02712034">study register, NCT02712034</a>	US	RCT	417	Medication-assisted treatment with mHealth	published February 2021	Publication new; (primary outcome testing, secondary viral load) <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694728">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694728</a> <a href="https://pubmed.ncbi.nlm.nih.gov/33616545">https://pubmed.ncbi.nlm.nih.gov/33616545</a>
The HALT Hepatitis study**	<a href="https://www.clinicaltrials.gov/ct2/show/study/ISRCTN2470735">study register, ISRCTN 2470735</a>	UK	RCT	364	Mobile screening of HCV or HBV, peer support	published/April 2019	Exclusion: ≤ 50 % PWID <a href="https://www.ucl.ac.uk/global-health/research/a-z/halt-hepatitis">https://www.ucl.ac.uk/global-health/research/a-z/halt-hepatitis</a>

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date*	Note/Associated publications
					and accompanied referrals		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442435/pdf/12916_2019_Article_1300.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442435/pdf/12916_2019_Article_1300.pdf</a>
Patient-Centered Models of HCV Care for People Who Inject Drugs (HERO)	<a href="#">study register, NCT02824640</a>	US	RCT	754	Directly observed therapy, patient navigators	ongoing/ 20 March 2020 (last update 23 March 2021)	Due to <a href="#">PCORI research program</a> study completion date is February, 2023
Opportunistic Hepatitis C Virus Treatment (Opportuni-C)	<a href="#">study register, NCT04220645</a>	NO	RCT	200	Hospitalised patients with HCV are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards	ongoing/30 September 2020 (final data collection date)	-
The DETECT HCV Linkage to Care Trial	<a href="#">study register, NCT04026867</a>	US	RCT	432	Clinical referral versus clinical referral and linkage navigator	ongoing/October 2021	-
Telemedicine for Linkage to Care People Who Injected Drugs With Hepatitis C	<a href="#">study register, NCT04035980</a>	ES	RCT	166	Telemedicine based programme	ongoing/31 December 2020 (final data collection date)	-

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date*	Note/Associated publications
Registry-based HCV Care Cascade Navigation at Atlanta's Grady Memorial Hospital	<a href="#">study register, NCT03441542</a>	US	RCT	80	Data-assisted Case Navigation for PWID or people on OST	unclear/1 August 2019 (final data collection date for primary outcome measure)	-
Reaching mEthadone Users Attending Community pHarmacies With HCV (REACH study)	<a href="#">study register, ct2/show/NCT03935906</a>	Scotland, Wales, AU	RCT (cluster)	140	Education-only HCV referral and treatment pathway versus a nurse-led point-of-care device testing and treatment pathway among OST patients in community pharmacies	ongoing/October 2022	-
Intensive Models of HCV Care for Injection Drug Users	<a href="#">study register, CT01857245</a>	US	RCT	150	Directly observed therapy; group treatment	published/May 2019	Study Akiyama et al. 2019 included in the review <a href="https://pubmed.ncbi.nlm.nih.gov/30959528">https://pubmed.ncbi.nlm.nih.gov/30959528</a>
Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs (TEMPO)	<a href="#">study register, NCT04014179</a>	AU/NZ	RCT	4 000	Compare two methods of testing to enhance HCV treatment uptake with peer support	ongoing/December 2024	-

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date*	Note/Associated publications
Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: validity, Acceptability and Impact on Linkage to Care	<a href="#">study register, NCT02084719</a>	CA	RCT	67	Primary aim: is evaluating rapid testing and if they can increase LtC	unclear/study completion date April 2016; no results published	Status of publication and if PWID included unclear
Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)	<a href="#">study register, NCT03214679</a>	US	RCT	300	Accessible Care: co-locating a hepatitis treatment provider together with a Hepatitis C Care Coordinator on-site at a needle exchange program	ongoing/30 July 2022	-
A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs	<a href="#">study register, NCT04428346</a>	AU	RCT	400	Financial incentives following dried blood spot hepatitis C testing	ongoing/December 2022	-
Treatment as Prevention for Hepatitis C in Iceland (TraP Hep C)	<a href="#">study register, NCT02647879</a>	IS	NRS	1000	Nationwide effort - all patients with	ongoing/May 2031	PWID mentioned

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date*	Note/Associated publications
					HCV infection will be offered treatment using direct acting antiviral agents		
Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care	<a href="#">study register, NCT03093415</a>	-	NRS	100	Treatment in community health clinic versus academic hepatology clinic versus needle exchange program	only results published November 2020	No details on method, exclusion
Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection (Care2Cure)	<a href="#">study register, NCT02707991</a>	US	RCT	68	Nurse case management	results published May 2019	<a href="#">Study Starbird et al. included in the review</a> <a href="https://pubmed.ncbi.nlm.nih.gov/31750598">https://pubmed.ncbi.nlm.nih.gov/31750598</a>
The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital	<a href="#">study register, NCT02555475</a>	AU	RCT	140	Primary care versus tertiary hospital	published/April 2020	<a href="#">Study Wade et al. included in the review</a> <a href="https://pubmed.ncbi.nlm.nih.gov/31233117">https://pubmed.ncbi.nlm.nih.gov/31233117</a>

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date*	Note/Associated publications
Rationale and design of a randomised pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study	<a href="#">Contemp Clin Trials, study protocol</a>	multisite	RCT	754	Patient navigation or directly observed therapy	unclear/study protocol published 2019	PWID included
CHAMPS Study: chronic Hepatitis C Management to ImProve OutcomeS	<a href="#">study register, NCT02402218</a>	US	RCT	144	Peer-mentors, cash incentives	published/April 2019	Study Ward et al. included in the review <a href="https://pubmed.ncbi.nlm.nih.gov/31049365">https://pubmed.ncbi.nlm.nih.gov/31049365</a>

AU: Australia; CA: Canada; ES: Spain; IS: Iceland; NO: Norway; NZ: New Zealand; US: United States

HCV: Hepatitis C virus; HBV: Hepatitis B virus; NA: not available; NRS: non randomised study; PWID: People Who Inject Drugs; RCT: randomised controlled trial

Update of status done on 14 April 2021.

\* **Status:** Search for ongoing studies, withdrawn, and completed studies identified in study registries was conducted in August 2020, an update of the status of ongoing/planned studies was conducted on 12/13 April 2021. **'Estimated' study completion date** = study completion date predicted by the researchers. The classification **'unclear'** is based on the following: (1) the study is marked as ongoing according to the register entry, but the planned end of the study was already in the past at the time of the update of the status (13 April 2021); (2) there is no information given about the end of the study, study may be continued and published; (3) only preliminary results are published to the register entry and may be continued; or (3) the status of the study is marked as "unknown" in the register.

\*\* Study assessed LtC and AtT for **HCV and HBV**



## HIV/HCV – ongoing, withdrawn, and completed studies

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date *	Note/Associated publications
The Stepped Care Intervention to Suppress Viral Load in Youth Living With HIV	<a href="#">study register, NCT03109431</a>	US	RCT	220	Automated messaging and monitoring Intervention, peer support, coaching	ongoing/31 May 2022	PWID not mentioned
Mobile technology intervention to improve care coordination between HIV and substance use treatment providers	<a href="#">study register, NCT02906215</a>	US	NRS	78	Care coordination intervention for providers	unclear/30 August 2020	Targeting providers serving people who use drugs
Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users (iTAB)	<a href="#">study register, NCT01317277</a>	US	RCT	75	Individualised texting for adherence	unclear/June 2014	only preliminary results published in 2013) <a href="https://pubmed.ncbi.nlm.nih.gov/24078868">https://pubmed.ncbi.nlm.nih.gov/24078868</a>
Youth to Text or Telehealth for Engagement in HIV Care	<a href="#">study register, NCT03681145</a>	US	(Pilot) RCT	50	Telehealth counselling	published/January 2021	New publication: Exclusion <50% PWID; <1 year duration <a href="https://pubmed.ncbi.nlm.nih.gov/33575683">https://pubmed.ncbi.nlm.nih.gov/33575683</a>
Youth Engagement Study: Intervention to Increase HIV Treatment	<a href="#">study register, NCT03665532</a>	US	RCT	400	Interventions to identify HIV positive people,	ongoing/30 June 2021	PWID not mentioned

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date *	Note/Associated publications
Engagement and Adherence for Young People Living With HIV					mHealth interventions, counselling		
WeiTelOAKTREE: Text Messaging to Support Patients With HIV/AIDS in British Columbia	<a href="#">study register, NCT02603536</a>	CAN	NRS	85	Text-message intervention for HIV adherence	published/1 June 2017	Exclusion <50% PWID <a href="https://pubmed.ncbi.nlm.nih.gov/28572079">https://pubmed.ncbi.nlm.nih.gov/28572079</a>
Using Community Based Participatory Research (CBPR) to Engage Hazardous Drinking Women in the HIV Prevention and Care Continuum	<a href="#">study register, NCT04090723</a>	US	RCT	60	Computer-delivered interventions for drinking reduction, improving HIV prevention and care continuum	ongoing/August 2022	PWID not mentioned
Use of Incentives to Retain Drug Users in HIV Therapy	<a href="#">study register, NCT01488942</a>	CAN	RCT	139	Incentives for drug users to retain HIV therapy	unclear/31 March 2018	No publication identified
Timely Initiation of HIV Antiretroviral Therapy Among Those Who Delay/Decline	<a href="#">study register, NCT02086630</a>	US	RCT	95	Video-components, patient navigation, support groups and Support partner	unclear/April 2015	No publication identified, PWID not mentioned
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care	<a href="#">study register, NCT01941108</a>	US	(Pilot) RCT	39	Peer health navigation supported by a smartphone application	published/April 2017	Exclusion: < 50% PWID; <1 year duration <a href="https://pubmed.ncbi.nlm.nih.gov/28441962">https://pubmed.ncbi.nlm.nih.gov/28441962</a>

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date *	Note/Associated publications
Suppression of HIV 1 RNA in People Living With HIV	<a href="#">study register, NCT02363387</a>	US	RCT	102	Incentives to promote long term suppression of HIV	ongoing/March 2021	-
Substance Treatment and HIV Testing and Referral System	<a href="#">study register, NCT01488630</a>	US	Pre-post	60	Computer assisted screening and referral system	unclear/March 2013 (final data collection date); last update posted July 2018	No publication identified
Using Patient Reported Outcomes and Care Managers to Improve HIV Medication Adherence in Routine Clinical Care	<a href="#">study register, NCT01505660</a>	US	RCT	270	Care management	unclear/June 2015 (final data collection date)	No publication identified
Project RETAIN: providing Integrated Care for HIV-Infected Crack Cocaine Users	<a href="#">study register, NCT01614106</a>	US	RCT	360	Integrated HIV primary care (substance abuse treatment, mental health services, patient navigation)	ongoing/December 2021	PWID not mentioned
Positive Health Check Evaluation Trial	<a href="#">study register, NCT03292913</a>	US	RCT	799	Interactive videos with HIV positive patients on improving clinical outcomes and retention in care	unclear/31 October 2020 (final data collection date)	No publication identified, PWID not mentioned
Pos4Health for Nonadherent HIV+ Substance Users	<a href="#">study register, NCT02837250</a>	US	(Pilot) RCT	51	Peer role model videos, interactions to promote coping and managing risk factors for nonadherence to ART, improve nonadherence	unclear/1 May 2018	No publication identified

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date *	Note/Associated publications
Minority AIDS Initiative Retention and Re-Engagement Project	<a href="#">study register, NCT01616940</a>	US	RCT	348	Peer intervention and patient navigation	publication August 2018	Exclusion: no PWID <a href="https://pubmed.ncbi.nlm.nih.gov/29306990">https://pubmed.ncbi.nlm.nih.gov/29306990</a>
Intervention to Retain HIV-positive Patients in Medical Care	<a href="#">study register, NCT01537367</a>	US	RCT		Personal contact with patients coupled with basic HIV education	results first posted/last updated August/September, 2013	Exclusion: no PWID
Integrated HIV Prevention and HCV Care for PWID**	<a href="#">study register, NCT03981445</a>	US	RCT	500	Adherence counselling, patient navigation	ongoing/July 2022	-
Improving Engagement in HIV Care for High-risk Women	<a href="#">study register, NCT03081559</a>	US	RCT	278	Peer-based counselling for adherence, engagement in care	ongoing/30 October 2020 (final data collection date)	No publication identified, PWID not mentioned
HIV + Substance Users Released From Jail	<a href="#">study register, NCT03834779</a>	US	(Pilot) RCT	31	Assistance in navigating social and medical services	ongoing/30 September 2021	-
Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial	<a href="#">study register, NCT02440256</a>	CA	RCT	49	Integrated care in OST to increase testing, treatment initiation and adherence	unclear/March 2017 study completion data, no results published	No publication identified
Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care	<a href="#">study register, NCT01406626</a>	US	RCT	356	Peer navigation	published/publication April 2018	Exclusion: no PWID <a href="https://pubmed.ncbi.nlm.nih.gov/29306990">https://pubmed.ncbi.nlm.nih.gov/29306990</a>

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date *	Note/Associated publications
							<a href="https://www.fda.gov/29532059">h.gov/29532059</a>
Care4Today v2.0 Application for Improving Adherence to HIV Medications	<a href="#">study register, NCT02001064</a>	US	(Pilot) RCT	65	Smart phone application titled "Care4Today v2.0" for medication adherence to ART over a 4-week period	unclear/only October 2016 only Poster presentation	Exclusion: poster presentation and study duration < 1 year
Building on Needle Exchange to Optimize Prevention & Treatment	<a href="#">study register, NCT03567174</a>	US	RCT	720	Integrated care van linked to mobile syringe service program	ongoing/July 2022	-
Adherence Intervention for HIV-infected Drug Users	<a href="#">study register, NCT02907697</a>	US	RCT	132	Focus groups, manual development, therapist training, interviews, health education	ongoing/December 30 2020	no results posted, 13.4.2021
A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults	<a href="#">study register, NCT02704208</a>	US	RCT	400	Mobile enhanced website adherence; technology-delivered peer-to-peer social support intervention with social networking and gaming components	ongoing/31 May 2021	PWID not mentioned
A Peer-based Mobile-health Intervention to Increase Access & Adherence to Hepatitis C	<a href="#">study register, NCT02772328</a>	US	RCT	300	Trained peer mentors	unclear/August 2020 (final data collection)	No publication identified,

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date *	Note/Associated publications
Treatment & HIV Viral Suppression**							PWID not mentioned
Text Messaging to Improve Linkage, Retention, and Health Outcomes Among HIV-Positive Young Transgender Women: Protocol for a Randomised Controlled Trial (Text Me, Girl!)	<a href="#">protocol, DERR1-10.2196/12837</a>	US	RCT	130	Impact of a 90-day, transgender-specific, text-messaging intervention	unclear/protocol published 31 August 2019	No final publication identified; exclusion: study duration < 1 year, unclear if PWID included
Strategies to Treat and Prevent HIV in the United States for Adolescents and Young Adults: Protocol for a Mixed-Methods Study	<a href="#">protocol, DERR1-10.2196/10759</a>	US	NRS/RCT	220	Text messages, weekly monitoring survey; peer support; coaching	ongoing/May 2021	PWID not mentioned
Computerized Substance Use and Depression Screening and Behavioral Treatment in HIV Primary Care (PACE)	<a href="#">study register, Nct03217058</a>	US	NRS	5 000	Self-administered tablet-based substance use disorders (SUD), depression screening at clinic visits, followed by SUD, anxiety, and depression by a behavioral health specialist.	ongoing/1 February 2021	Secondary outcome viral load
Text-Messaging, Online Peer Support Group, and Coaching Strategies to Optimize the HIV Prevention Continuum for Youth: Protocol for a	<a href="#">study register, NCT03134833</a>	US	RCT	1 478	Automated messaging and monitoring intervention, peer support, coaching	ongoing/31 May 2022	PWID not mentioned

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status /estimated study completion date *	Note/Associated publications
Randomised Controlled Trial							
Motivational Assessment Program to Initiate Treatment (MAPIT)	<a href="#">study register, NCT01891656</a>	US	RCT	360	Motivational computer intervention (MAPIT); in-person motivational interviewing	published/September 2017	Exclusion: < 1-year study duration, < 50 % PWID <a href="https://pubmed.ncbi.nlm.nih.gov/28755774">https://pubmed.ncbi.nlm.nih.gov/28755774</a>
Substance Abuse Treatment to HIV Care (SAT2HIV): The Motivational Interviewing-based Brief Intervention Experiment	<a href="#">study register, NCT02495402</a>	US	RCT	827	Motivational interviewing-based intervention for substance use	unclear	No publication identified
LinkPositively: a Technology-Delivered Peer Navigation and Social Networking Intervention to Improve HIV Care	<a href="#">study register, NCT04199052</a>	US	(Pilot) RCT	82	Virtual Peer Navigation Social Networking platform, educational, self-monitoring, reminders	ongoing/November 2022	

CA: Canada; US: United States

HCV: Hepatitis C virus; HIV: Human Immunodeficiency Virus; NRS: non-randomised study; PWID: People Who Inject Drugs; RCT: randomised controlled trial

Update of status done on 14 April 2021.

\* **Status:** Search for ongoing studies, withdrawn, and completed studies identified in study registries was conducted in August 2020, an update of the status of ongoing/planned studies was conducted on 12/13 April 2021. '**Estimated**' study completion date' = study completion date predicted by the researchers. The classification '**unclear**' is based on the following: (1) the study is marked as ongoing according to the register entry, but the planned end of the study was already in the past at the time of the update of the status (13 April 2021); (2) there is no information given about the end of the study, study may be continued and published; (3) only preliminary results are published to the register entry and may be continued; or (3) the status of the study is marked as "unknown" in the register.

\*\* Study assessed LtC/AtT for HIV and HCV.



## TB – ongoing, withdrawn, and completed TB studies

Title	Study Document type, register ID	Location	Study type	No of participants	Intervention(s)	Status / estimated study completion date*
An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for Tuberculosis Treatment	<a href="#">study register, NCT03266003</a>	US	RCT	304	directly observed therapy (DOT) and electronic forms of DOT	ongoing/31 December 2020 (no results posted, 13 April 2021)

TB: tuberculosis; RCT: randomised control trial; US: United States

Update of status done on 14 April 2021.

\* **Status:** Search for ongoing studies, withdrawn, and completed studies identified in study registries was conducted in August 2020, an update of the status of ongoing/planned studies was conducted on 12/13 April 2021. "**Estimated study completion date**" = study completion date predicted by the researchers. The classification '**unclear**' is based on the following: (1) the study is marked as ongoing according to the register entry, but the planned end of the study was already in the past at the time of the update of the status (13 April 2021); (2) there is no information given about the end of the study, study may be continued and published; (3) only preliminary results are published to the register entry and may be continued; or (3) the status of the study is marked as 'unknown' in the register.